Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Acta Diabetologica

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00592-015-0732-1PMID 25805649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

  2015cited by this paper
• Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

  2014cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

  2013cited by this paper
• Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials

  2011cited by this paper
• Hypoglycemia with intensive insulin therapy after cardiac surgery: predisposing factors and association with mortality.

  2011cited by this paper
• Hypoglycemia with intensive insulin therapy in critically ill patients: Predisposing factors and association with mortality*

  2009cited by this paper
• Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.

  2008cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Validation of a combined comorbidity index.

  1994cited by this paper

• Factor analysis as a tool to explore the heterogeneity of type 2 diabetes: a feasibility study.

  2022cites this paper
• "Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: a retrospective cohort study".

  2021cites this paper
• Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation

  2020cites this paper
• Predictors of treatment response in type‐2 diabetes patients initiating basal‐supported oral therapy with insulin glargine 100 U/mL: A sub‐analysis of the Titration and OPtimisation (TOP) registry

  2019cites this paper
• Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?

  2018cites this paper
• Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

  2018cites this paper
• Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

  2018cites this paper
• Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials

  2017cites this paper
• Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat‐to‐target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

  2017cites this paper
• [The safety of anti-diabetic drugs in heart failure].

  2017cites this paper
• Association of glucagon‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system

  2017cites this paper
• A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes

  2016cites this paper
• Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials

  2016cites this paper
• Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials

  2016cites this paper
• Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin

  2016cites this paper
• Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis

  2016cites this paper
• Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes

  2016cites this paper
• Enhanced external counterpulsation (EECP) improves biomarkers of glycemic control in patients with non-insulin-dependent type II diabetes mellitus for up to 3 months following treatment

  2016cites this paper
• Erratum to: Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials

  2016cites this paper